Evaluation of RevA, a fibronectin-binding protein of Borrelia burgdorferi, as a potential vaccine candidate for Lyme disease

Clinical and Vaccine Immunology

Volumn 20, Issue 6, 2013, Pages 842-847

  Floden, Angela M ^a   Gonzalez, Tammy ^a   Gaultney, Robert A ^a   Brissette, Catherine A ^a  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; BACTERIUM ANTIBODY; FIBRONECTIN BINDING PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROTEIN REVA; UNCLASSIFIED DRUG; BACTERIAL VACCINE; OUTER MEMBRANE PROTEIN; RECOMBINANT VACCINE; REVA PROTEIN, BORRELIA BURGDORFERI;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGENICITY; ARTICLE; BACTERICIDAL ACTIVITY; BORRELIA BURGDORFERI; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IN VITRO STUDY; LYME DISEASE; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTECTION; TICK BITE; VACCINATION; ANIMAL; BACTERIAL LOAD; BAGG ALBINO MOUSE; C3H MOUSE; DISEASE MODEL; IMMUNOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL LOAD; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; DISEASE MODELS, ANIMAL; FEMALE; IMMUNIZATION, PASSIVE; LYME DISEASE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; TREATMENT OUTCOME; VACCINES, SYNTHETIC;

EID: 84891457308     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00758-12     Document Type: Article

References (48)

1. Centers for Disease Control and Prevention. 2011. Summary of notifiable diseases - United States, 2009. Morb. Mortal. Wkly. Rep. 58:1-100.
2. Stanek G, Wormser GP, Gray J, Strle F. 2012. Lyme borreliosis. Lancet 379:461-473.
3. Nigrovic LE, Thompson KM. 2007. The Lyme vaccine: a cautionary tale. Epidemiol. Infections 135:1-8.
4. de Souza MS, Smith AL, Beck DS, Terwilliger GA, Fikrig E, Barthold SW. 1993. Long-term study of cell-mediated responses to Borrelia burgdorferi in the laboratory mouse. Infect. Immun. 61:1814-1822.
5. Stanek G, Strle F. 2003. Lyme borreliosis. Lancet 362:1639-1647. (Pubitemid 37443533)
6. Steere AC. 2001. Lyme disease. N. Engl. J. Med. 345:115-125. (Pubitemid 32640193)
7. Zhang J-R, Norris SJ. 1998. Genetic variation of the Borrelia burgdorferi gene vlsE involves cassette-specific, segmental gene conversion. Infect. Immun. 66:3698-3704. (Pubitemid 28347826)
8. Zhang J-R, Norris SJ. 1998. Kinetics and in vivo induction of genetic variation of vlsE in Borrelia burgdorferi. Infect. Immun. 66:3689-3697. (Pubitemid 28347825)
9. Bankhead T, Chaconas G. 2007. The role of VlsE antigenic variation in the Lyme disease spirochete: persistence through a mechanism that differs from other pathogens. Mol. Microbiol. 65:1547-1558. (Pubitemid 47347839)
10. Palmer GH, Bankhead T, Lukehart SA. 2009. 'Nothing is permanent but change'-antigenic variation in persistent bacterial pathogens. Cell. Microbiol. 11:1697-1705.
11. Eicken C, Sharma V, Klabunde T, Lawrenz MB, Hardham JM, Norris SJ, Sacchettini JC. 2002. Crystal structure of Lyme disease variable surface antigen VlsE of Borrelia burgdorferi. J. Biol. Chem. 277:21691-21696. (Pubitemid 34952320)
12. Cabello FC, Godfrey HP, Newman SA. 2007. Hidden in plain sight: Borrelia burgdorferi and the extracellular matrix. Trends Microbiol. 15:350-354. (Pubitemid 47126852)
13. Coburn J, Medrano M, Cugini C. 2002. Borrelia burgdorferi and its tropisms for adhesion molecules in the joint. Curr. Opin. Rheumatol. 14:394-398. (Pubitemid 34693983)
14. Franz JK, Fritze O, Rittig M, Keysser G, Priem S, Zacher J, Burmester GR, Krause A. 2001. Insights from a novel three-dimensional in vitro model of Lyme arthritis: standardized analysis of cellular and molecular interactions between Borrelia burgdorferi and synovial explants and fibroblasts. Arthritis Rheum. 44:151-162. (Pubitemid 32113129)
15. Häupl T, Hahn G, Rittig M, Krause A, Schoerner C, Schonherr U, Kalden JR, Burmester GR. 1993. Persistence of Borrelia burgdorferi in ligamentous tissue from a patient with chronic Lyme borreliosis. Arthritis Rheum. 36:1621-1626. (Pubitemid 23327762)
16. Asbrink E, Hovmark A. 1988. Early and late cutaneous manifestations in Ixodes-borne borreliosis (erythema migrans borreliosis, Lyme borreliosis), p 4-15. In Benach JL, Bosler EM (ed), Lyme disease and related disorders. New York Academy of Sciences, New York, NY.
17. Berger BW. 1989. Dermatologic manifestations of Lyme disease. Rev. Infect. Dis. 11(Suppl 6):S1475-S1481.
18. Ohlenbusch A, Matuschka FR, Richter D, Christen HJ, Thomssen R, Spielman A, Eiffert H. 1996. Etiology of the acrodermatitis chronica atrophicans lesion in Lyme disease. J. Infect. Dis. 174:421-423. (Pubitemid 26251436)
19. Brissette CA, Bykowski T, Cooley AE, Bowman A, Stevenson B. 2009. Borrelia burgdorferi RevA antigen binds host fibronectin. Infect. Immun. 77:2802-2812.
20. Coburn J. 2001. Adhesion mechanisms of the Lyme disease spirochete, Borrelia burgdorferi. Curr. Drug Targets Infect. Disord. 1:171-179.
21. Grab DJ, Givens C, Kennedy R. 1998. Fibronectin-binding activity in Borrelia burgdorferi. Biochim. Biophys. Acta 1407:135-145. (Pubitemid 28345163)
22. Seshu J, Esteve-Gassent MD, Labandeira-Rey M, Kim JH, Trzeciakowski JP, Hook M, Skare JT. 2006. Inactivation of the fibronectin-binding adhesin gene bbk32 significantly attenuates the infectivity potential of Borrelia burgdorferi. Mol. Microbiol. 59:1591-1601.
23. Li X, Liu X, Beck DS, Kantor FS, Fikrig E. 2006. Borrelia burgdorferi lacking BBK32, a fibronectin-binding protein, retains full pathogenicity. Infect. Immun. 74:3305-3313. (Pubitemid 43794518)
24. Nowalk AJ, Gilmore RD, Jr, Carroll JA. 2006. Serologic proteome analysis of Borrelia burgdorferi membrane-associated proteins. Infect. Immun. 74:3864-3873. (Pubitemid 43993317)
25. Gilmore RD, Jr, Mbow ML, Stevenson B. 2001. Analysis of Borrelia burgdorferi gene expression during life cycle phases of the tick vector Ixodes scapularis. Microbes Infect. 3:799-808. (Pubitemid 32913162)
26. Brissette CA, Rossmann E, Bowman A, Cooley AE, Riley SP, Hunfeld KP, Bechtel M, Kraiczy P, Stevenson B. 2010. The borrelial fibronectin-binding protein RevA is an early antigen of human Lyme disease. Clin. Vaccine Immunol. 17:274-280.
27. Casjens S, Palmer N, van Vugt R, Huang WM, Stevenson B, Rosa P, Lathigra R, Sutton G, Peterson J, Dodson RJ, Haft D, Hickey E, Gwinn M, White O, Fraser C. 2000. A bacterial genome in flux: the twelve linear and nine circular extrachromosomal DNAs of an infectious isolate of the Lyme disease spirochete Borrelia burgdorferi. Mol. Microbiol. 35:490-516. (Pubitemid 30085269)
28. Fraser CM, Casjens S, Huang WM, Sutton GG, Clayton R, Lathigra R, White O, Ketchum KA, Dodson R, Hickey EK, Gwinn M, Dougherty B, Tomb J-F, Fleischmann RD, Richardson D, Peterson J, Kerlavage AR, Quackenbush J, Salzberg S, Hanson M, van Vugt R, Palmer N, Adams MD, Gocayne J, Weidmann J, Utterback T, Watthey L, McDonald L, Artiach P, Bowman C, Garland S, Fujii C, Cotton MD, Horst K, Roberts K, Hatch B, Smith HO, Venter JC. 1997. Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi. Nature 390:580-586. (Pubitemid 28016185)
29. Miller JC, von Lackum K, Babb K, McAlister JD, Stevenson B. 2003. Temporal analysis of Borrelia burgdorferi Erp protein expression throughout the mammal-tick infectious cycle. Infect. Immun. 71:6943-6952. (Pubitemid 37475325)
30. Zückert WR. 2007. Laboratory maintenance of Borrelia burgdorferi. Curr. Protoc. Microbiol. Chapter 12:Unit 12C.1. doi:10.1002/9780471729259. mc12c01s4.
31. Bunikis I, Kutschan-Bunikis S, Bonde M, Bergstrom S. 2011. Multiplex PCR as a tool for validating plasmid content of Borrelia burgdorferi. J. Microbiol. Methods 86:243-247.
32. Ornstein K, Barbour AG. 2006. A reverse transcriptase-polymerase chain reaction assay of Borrelia burgdorferi 16S rRNA for highly sensitive quantification of pathogen load in a vector. Vector Borne Zoonotic Dis. 6:103-112.
33. Breitner-Ruddock S, Würzner R, Schulze J, Brade V. 1997. Heterogeneity in the complement-dependent bacteriolysis within the species of Borrelia burgdorferi. Med. Microbiol. Immunol. 185:253-260.
34. Brissette CA, Cooley AE, Burns LH, Riley SP, Verma A, Woodman ME, Bykowski T, Stevenson B. 2008. Lyme borreliosis spirochete Erp proteins, their known host ligands, and potential roles in mammalian infection. Int. J. Med. Microbiol. 298(Suppl 1):257-267.
35. Herzberger P, Siegel C, Skerka C, Fingerle V, Schulte-Spechtel U, van Dam A, Wilske B, Brade V, Zipfel PF, Wallich R, Kraiczy P. 2007. Human pathogenic Borrelia spielmanii sp. nov. resists complement-mediated killing by direct binding of immune regulators factor H and factor H-like protein 1. Infect. Immun. 75:4817-4825. (Pubitemid 47502151)
36. Kurtenbach K, Sewell H-S, Ogden NH, Randolph SE, Nuttall PA. 1998. Serum complement sensitivity as a key factor in Lyme disease ecology. Infect. Immun. 66:1248-1251.
37. van Dam AP, Oei A, Jaspars R, Fijen C, Wilske B, Spanjaard L, Dankert J. 1997. Complement-mediated serum sensitivity among spirochetes that cause Lyme disease. Infect. Immun. 65:1228-1236.
38. Carroll JA, El-Hage N, Miller JC, Babb K, Stevenson B. 2001. Borrelia burgdorferi RevA antigen is a surface-exposed outer membrane protein whose expression is regulated in response to environmental temperature and pH. Infect. Immun. 69:5286-5293. (Pubitemid 32786459)
39. Gilmore RD, Jr, Mbow ML. 1998. A monoclonal antibody generated by antigen inoculation via tick bite is reactive to the Borrelia burgdorferi Rev protein, a member of the 2.9 gene family locus. Infect. Immun. 66:980-986. (Pubitemid 28101136)
40. Mbow ML, Gilmore RD, Jr, Stevenson B, Golde WT, Piesman J, Johnson BJB. 2002. Borrelia burgdorferi-specific monoclonal antibodies derived from mice primed with Lyme disease spirochete-infected Ixodes scapularis ticks. Hybrid Hybridomics 21:179-182. (Pubitemid 35007523)
41. Henderson B, Nair S, Pallas J, Williams MA. 2011. Fibronectin: a multidomain host adhesin targeted by bacterial fibronectin-binding proteins. FEMS Microbiol. Rev. 35:147-200.
42. Brooks CS, Hefty PS, Jolliff SE, Akins DR. 2003. Global analysis of Borrelia burgdorferi genes regulated by mammalian host-specific signals. Infect. Immun. 71:3371-3383. (Pubitemid 36637565)
43. Caimano MJ. 2005. Cultivation of Borrelia burgdorferi in dialysis membrane chambers in rat peritonea. Curr. Protoc. Microbiol. Chapter 12:Unit 12C.3. doi:10.1002/9780471729259.mc12c03s00.
44. Hastey CJ, Elsner RA, Barthold SW, Baumgarth N. 2012. Delays and diversions mark the development of B cell responses to Borrelia burgdorferi infection. J. Immunol. 188:5612-5622.
45. Kramer MD, Schaible UE, Wallich R, Moter SE, Petzoldt D, Simon MM. 1990. Characterization of Borrelia burgdorferi associated antigens by monoclonal antibodies. Immunobiology 181:357-366.
46. Luft BJ, Dunn JJ, Lawson CL. 2002. Approaches toward the directed design of a vaccine against Borrelia burgdorferi. J. Infect. Dis. 185(Suppl 1):S46-S51. (Pubitemid 34142828)
47. Barthold SW, Moody KD, Terwilliger GA, Duray PH, Jacoby RO, Steere AC. 1988. Experimental Lyme arthritis in rats infected with Borrelia burgdorferi. J. Infect. Dis. 157:842-846. (Pubitemid 18093753)
48. Steere AC, Grodzicki RL, Kornblatt AN, Craft JE, Barbour AG, Burgdorfer W, Schmid GP, Johnson E, Malawista SE. 1983. The spirochetal etiology of Lyme disease. N. Engl. J. Med. 308:733-740. (Pubitemid 13158637)